CLINICAL_TRIALS
trial_result
· 2025-01-14
Clinical Trial Update: Study of Evobrutinib in Participants With RMS (evolutionRMS 2) [Phase 3]
Summary
A Phase 3 study of evobrutinib in relapsing multiple sclerosis was terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Conditions: Relapsing Multiple Sclerosis | Phase 3 | Status: TERMINATED | Results posted: 2025-01-14